Find what the market hasn't priced in
Sleuth gives investment teams a single workspace to diligence opportunities, monitor portfolios, and track competition across therapeutic areas. From preclinical diligence to portfolio catalyst tracking, faster conviction on every decision.
Placing bets where the data is thinnest
The thesis changes while you're not watching
You're tracking portfolio companies, active diligences, and new opportunities. A competitor readout or deal announcement can change the thesis on any of them. Your LPs expect you to see it coming.
Diligence on a handful of posters
The most interesting companies are preclinical or platform-stage. Public data is sparse. You're evaluating the science, the team, the market position, and exit path from conference abstracts and a pitch deck.
The round closes before your diligence does
A competitive financing closes in weeks. Every day spent assembling a landscape is a day closer to losing allocation. You need depth on the timeline the deal sets.
Built for how investment teams actually work
Stay current across your entire thesis
Sleuth monitors competitive landscapes, clinical readouts, deal activity, and sell-side consensus shifts across your portfolio and pipeline. When something changes the thesis, your view already reflects it.
Early-stage coverage your diligence depends on
Sleuth's knowledge graph covers 100K+ drugs, roughly half preclinical, with connections across patents, abstracts, and company disclosures. You diligence platform-stage companies from a real foundation.
Depth on the deal's timeline
Sleuth compresses competitive landscaping, mechanism validation, and deal precedent analysis from weeks to days. You spend your diligence window pressure-testing the thesis, not assembling it.